SEC Form 4 · accession 0001493152-16-015111
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Nov 10, 2016
Accepted (ET)
Nov 15, 2016 · 3:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 10, 2016 | J | 9,663 | $0.78 | D | 3,186,452 | D | |
| Common StockF2 | Nov 10, 2016 | J | 17,096 | $0.78 | D | 3,169,356 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Distributed as an in-kind distribution to a withdrawing limited partner in 10X Fund, LP.
- F210X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.